INTRODUCTION
L ornoxicam, (6-chloro-4-hydroxy-2-methyl-N-2-pyridinyl-2H-thieno[2,3-e]-1,2-thiazine-3-carboxamide 1,1-dioxide, C 13 H 10 ClN 3 O 4 S 2 , Figure 1 ) is a non-steroidal anti-infl ammatory drug with analgesic and antipyretic properties that belongs to the class of oxicams. It acts by nonselective inhibition of cyclo-oxygenase-1 and -2. It is prescribed for osteoarthritis, rheumatoid arthritis, acute lumbar-sciatica conditions and postoperative pain management (1) .
In the literatures, a voltammetric (2), polarograhic (3), UV spectrophotmetric (4), LC/MS/MS (5-6), TLC-densitometry (7) , and high performance liquid chromatographic (HPLC) (7-11) methods were reported for the analysis of lornoxicam. All the reported HPLC methods used buff er in the mobile phase and long retention time. Th e present study was aimed to develop a simple, rapid, precise, accurate and selective chromatographic method for the estimation of lornoxicam in bulk and dosage forms without the use of buff er in the mobile phase in short duraion. 
EXPERIMENTAL

Chemicals and reagents
Bulk sample of lornoxicam was obtained from Hetero drugs, Hyderabad, India. Th e commercial samples of tablets containing 4 mg and 8 mg of lornoxicam were purchased from local market (T1 and T2). Milliq water (Millipore) water was used throughout the work. Methanol (HPLC grade) and Formic acid (HPLC grade) were procured from Sigma Aldrich (Switzerland).
Equipment
A Agilent LC system consisted of a solvent delivery system, an auto-injector fi tted with 100 μL syringe, an online degasifi cation system, and an UV/VIS photodiode array detector. Th e output signal was monitored and integrated using chem. station software (Agilent).
Chromatographic condition
A Agilent 1200, (Germany) HPLC instrument with a Zorbax eclipse XBD C-18 analytical column, (150 mm × 4.6 mm, 5 μm) was used for the study. Th e mobile phase used was methanol-water with 0.1% formic acid in water (80:20 v/v), with a fl ow rate of 0.8 ml/min. UV detection was made at 381 nm. Th e volume of injection was fi xed at 20 μl. All analyses were done at ambient temperature. Th e mobile phase was prepared freshly and vacuumfi ltered through a 0.45 μm Millipore nylon fi lters in the beginning of the experiment.
Preparation of standard stock solutions
Th e stock solution of lornoxicam (100 μg/ml) was prepared by dissolving 10 mg of Lornoxicam (99.8 %) in methanol in a standard 100 mL volumetric fl ask. Aliquots of 0.5 to 20 μg/ml were prepared from the stock solution.
Sample preparation
Twenty tablets were weighed and their average weight was calculated. Th e tablets were crushed into a homogeneous powder and a quantity equivalent to one tablet (4 mg, and 8 mg) was transferred to a 50 mL volumetric fl ask, dissolved in methanol and fi ltered through a 0.45 μm Millipore nylon fi lters.
Recommended procedure for standard graph
After a systematic and detailed study of various parameters involved, the following procedure and conditions are recommended for the determination of lornoxicam in pure samples and in dosage forms.
Th e calibration curve for lornoxicam was constructed by analyzing lornoxicam solutions containing 0.5 to 20.0 μg/ml in triplicate. Th e standard solutions were prepared by diluting the stock solution in mobile phase. Each of these samples (20 μl) was injected three times into the column and the peak area of absorption was determined. Standard graph was plotted by taking concentration of drug on x-axis and peak area of absorption on y-axis.
Quantification of Lornoxicam
Suitable dilutions of both the tablets were made with mobile phase so as to obtain a concentration of the drug in the range of linearity determined. Volume of sample injected into the column was 20 μl. All the determinations were made in triplicate.
METHOD VALIDATION Linearity
Th e standard curve was prepared in the concentration range of 0.5 to 20.0 μg/mL for lornoxicam. Th e linearity of these methods was evaluated by linear regression analysis, using least square analysis method.
Precision
Th e precision of the assay was determined in terms of repeatability (intra-day) and intermediate (interday) precision. Th e intra and inter-day variation in the peak area of drug solution containing 4 μg/mL of lornoxicam were calculated in terms of RSD (Relative standard deviation).
Accuracy
Th e accuracy of HPLC method was assessed by adding known amount of drug to a drug solution of pre-analyzed sample and subjected to the proposed HPLC method (12-13). All solutions were prepared and analyzed in triplicate.
Limit of detection (LOD.) and limit of quantification (LOQ.)
Th e LOD and LOQ were determined for HPLC method. Th e limits were determined based on the standard deviation amongst response and slope of the curve at lowest concentrations (International Conference on Harmonization, 1997). Th e obtained theoretical values for LOD and LOQ were actually prepared and were cross checked by actual analysis using proposed method.
RESULTS AND DISCUSSION
To develop a suitable and robust LC method for the determination of lornoxicam diff erent mobile phases and columns were employed to achieve the effi cient separation and resolution. Th e criteria employed for selecting the mobile phase for the analyses of the drugs were cost involved and time required for the analysis. Attempts with traditional reverse phase columns presented poor peak symmetry and tailing problem. Most of the separation methods in literature overcame these problems by use of buff ers in mobile phase (14) . Th e proposed method was able to selectively separate lornoxicam in a short chromatographic run (less than 3 min) without the use of buff er mobile phase. Th e retention time is 2.63 min. Th e chromatogram is shown in Figure 2 .
System suitability
System suitability tests were performed as per the USP 31 to confi rm the suitability and reproducibility of the system. Th e test was carried out by injecting 20 μl standard solutions of lornoxicam 10 μg/ml. Th is was repeated fi ve times. Th e RSD values of lornoxicam were ±0.52. Th e RSD values were found to be satisfactory and meeting the requirements of USP 31.
Th eoretical plates, tailing factor were determined and are presented in Table 1 .
Linearity
Linearity was evaluated by analysis of working standard solutions of lornoxicam of six diff erent concentrations. Th e range of linearity was from 0.5 -20 μg/ml. Th e peak area and concentration of each drug was subjected to regression analysis to calculate the calibration equations and correlation coeffi cients. Th e regression data obtained are represented in Table 1 . Th e result shows that within the concentration range mentioned above, there was an excellent correlation between peak area and concentration of drug.
Limit of detection and limits of quantitation
Th e limit of detection (LOD) and limit of quantitation (LOQ) were established as per the ICH guidelines. Limit of detection and limit of quantifi cation were found to be 0.013 μg/ml and 0.465 μg/ml of lornoxicam respectively (Table 1) .
Precision
Th e method precision was evaluated by inter and intra-day repeatability. RSD values were found to be well below 1.52 % for intra-day repeatability and below 1.05 % for inter day repeatability indicating good precision of method (Table 1) .
Accuracy
To study accuracy of the method, recovery experiment was carried out by applying the standard addition method. A known quantity of each drug substance corresponding to 50%, 100% and 150% of the label claim of each drug was added, to determine if there are positive or negative interferences from excipients present in the formulation (12) (13) . Each set of addition was repeated three times. Th e accuracy was expressed as the percentage of analytes recovered by the assay. Table 2 lists the recoveries of the drugs from a series of spiked concentrations. Th e results indicate the method is highly accurate for s determination of the lornoxicam. 
Specificity
Specifi city is the ability of the method to accurately measure the analyte response in the presence of all potential sample components (excipients). Th e results were compared with the analysis of a standard lornoxicam and tablet formulations. Excipients of the solid dosage form did not interfere with the analyte.
CONCLUSION
Th e proposed method for quantitative determination of lornoxicam in pharmaceutical formulation is effi cient and sensitive. Th e excipients of the commercial sample analyzed did not interfere in the analysis, which proved the specifi city of the method for these formulations. Th e HPLC method was found to be simple, rapid, precise, accurate and sensitive. Its advantages over other existing methods are its low-cost, non usage of buff ers and less time consuming. Th is method can be used for routine quality control of lornoxicam in commercial samples.
